Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.71 |
| ▸ | DPP4 | P27487 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.71 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.71 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.71 |
| ▸ | GAPDH | P04406 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | STAT6 | P42226 | 1/20 | 0.71 |
| ▸ | PI4KA | P42356 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.71 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.71 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.71 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.71 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15788449 | 0.91 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL15926827 | 0.91 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL384075 | 0.91 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL29936504 | 0.91 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL15338502 | 0.91 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL15338536 | 0.91 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL41361 | 0.91 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL3446755 | 0.90 | ADORA1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8164443 | 0.89 | P2RY1 (0.68) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| Water SCHEMBL4262656 | 0.89 | ADORA1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103319555-A | Preparation method of 2'-methoxy adenosine | HUAIHAI INST TECHNOLOGY | 2013-09-25 | — | — | CN | claimed |
| CN-102058614-A | Use of adenosine receptor agonists in therapy | CAMBRIDGE BIOTECHNOLOGY LTD | 2011-05-18 | — | — | CN | claimed |
| CN-100355769-C | 2'-methoxy adenosine preparation method | UNIV EAST CHINA NORMAL (CN) | 2007-12-19 | — | — | CN | claimed |
| CN-1886414-A | Improved synthesis of 2-substituted adenosines | BIOVITRUM AB (SE) | 2006-12-27 | — | — | CN | claimed |
| CN-1765913-A | 2'-methoxy adenosine preparation method | UNIV EAST CHINA NORMAL (CN) | 2006-05-03 | — | — | CN | claimed |
| WO-1999051761-A1 | IMPROVEMENTS IN OR RELATING TO NUCLEIC ACID SYNTHESIS AND SELECTION | MEDICAL RESEARCH COUNCIL (GB) | 1999-10-14 | — | — | WO | claimed |
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| CN-120157727-A | Chemically modified adenine nucleoside triphosphate and preparation method and application thereof | 中国科学院深圳先进技术研究院 | 2025-06-17 | — | — | CN | disclosed |
| CN-120118909-A | SiRNA duplex for targeted regulation of LPA gene expression and application thereof in preventing and treating cardiovascular and cerebrovascular related diseases | 北京悦康科创医药科技股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119799706-A | SiRNA for targeted regulation of HBV gene expression and application thereof | 杭州天龙药业有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119799705-A | SiRNA for targeted regulation of HBV gene expression and application thereof | 杭州天龙药业有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119752912-A | SiRNA for targeted regulation of HBV gene expression and application thereof | 杭州天龙药业有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119219711-B | Preparation method of 2' -modified basic nucleoside | 上海科泽永欣生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20050043268-A1 | Inhibition of viruses | MEDICAL RESEARCH COUNCIL (GB) | 2005-02-24 | — | — | US | disclosed |
| WO-2004078183-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2004-09-16 | — | — | WO | disclosed |
| WO-1999051761-A1 | IMPROVEMENTS IN OR RELATING TO NUCLEIC ACID SYNTHESIS AND SELECTION | MEDICAL RESEARCH COUNCIL (GB) | 1999-10-14 | — | — | WO | disclosed |
| WO-1998001459-A1 | NOVEL N-ALKOXYADENINE DERIVATIVES ACTING AS CYTOKINE INHIBITORS | NOVO NORDISK A/S (DK) | 1998-01-15 | — | — | WO | disclosed |
| WO-1997033591-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| EP-0719275-A1 | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007921-A1 | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043268-A1 | Inhibition of viruses | RNASE1, HNRNPA1, RNASEH1 | ADORA1 237/4885SMN1; SMN2 421/4885ADORA3 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.